1 |
Chun YJ, Kim CY. The factors influencing variation by local areas in antibiotics prescription rate according to the public reporting. Health Policy Manag 2012;22(3):427-450. DOI: https://doi.org/10.4332/kjhpa.2012.22.3.427.
DOI
|
2 |
Park S, Kim D, Park E, Lee S, Kim S. Study on the post management of pharmaceutical pricing. Wonju: National Health Insurance Service, Korea Institute for Health and Social Affairs; 2015.
|
3 |
World Health Organization Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment. Oslo: Collaborating Centre for Drug Statistics Methodology; 2018.
|
4 |
Farnier M, Davignon J. Current and future treatment of hyperlipidemia: the role of statins. Am J Cardiol 1998;82(4B):3J-10J. DOI: https://doi.org/10.1016/s0002-9149(98)00423-8.
DOI
|
5 |
Lee HJ, Lee TJ. Impact of price control on drug expenditure and factors associated with the drug switch among statins: analysis of HIRA-NPS data. Health Policy Manag 2013;23(2):112-123. DOI: https://doi.org/10.4332/kjhpa.2013.23.2.112.
DOI
|
6 |
Health Insurance Review and Assessment Service. 2016 Statistical index of national health insurance spending. Wonju: Health Insurance Review and Assessment Service; 2017.
|
7 |
Shibata S, Matsushita M, Saito Y, Suzuki T. Anticancer drug prescription patterns in Japan: future directions in cancer therapy. Ther Innov Regul Sci 2018;52(6):718-723. DOI: https://doi.org/10.1177/2168479017751404.
DOI
|
8 |
Bach PB, Giralt SA, Saltz LB. FDA approval of tisagenlecleucel: promise and complexities of a $475 000 cancer drug. JAMA 2017;318(19):1861-1862. DOI: https://doi.org/10.1001/jama.2017.15218.
DOI
|
9 |
Lee EK, Park E. Policy issues on drug listing of national health insurance. Public Health Welf Forum 2005;(103):103-112.
|
10 |
Bae EY. Study on the drug expenditure trend in Korea. Korean J Health Econ Policy 2007;13(2):39-54.
|
11 |
Choi YJ, Shalowitz JI. Major growths of Korean pharmaceutical expenditure. Korean J Soc Health Inf Stat 2011;36(1):15-24.
|
12 |
Lee SM, Kim NS. The development research on prescribing incentive model to reduce prescribing cost in health insurance system. Korean J Health Econ Policy 2010;16(3):63-89.
|
13 |
Kim SO, Lee JH, Shin KY. Roadmap of the management of NHI pharmaceutical expenditure: annual report of NHIS Health Insurance Policy Research Institute. Wonju: National Health Insurance Service; 2012.
|
14 |
Woo S. The issues on Korean pharmaceutical pricing policies and suggestions for reform. Welf Trends 2006;(92):52-59.
|
15 |
Sakong J, Lee K. A study on the effect of the policy for the optimization of the pharmaceutical expenditures in Korean National Health Insurance System. Korean J Health Econ Policy 2007;13(1):139-172.
|
16 |
Kwon HY, Yang BM. Fixed budget for pharmaceuticals. Korean J Health Econ Policy 2011;17(1):25-45.
|
17 |
Kim DS, Bae S, Jang S. Lessons from generic promotion policies in other countries. Korean J Health Policy Adm 2013;23(3):210-223. DOI: https://doi.org/10.4332/kjhpa.2013.23.3.210.
DOI
|
18 |
Organization for Economic Cooperation and Development. OECD health data: pharmaceutical spending [Internet]. Paris: Organization for Economic Cooperation and Development; 2018 [cited 2018 Apr 10]. Available from: https://data.oecd.org/healthres/pharmaceutical-spending.htm.
|
19 |
Health Insurance Review and Assessment Service. 2017 Statistical index of national health insurance spending. Wonju: Health Insurance Review and Assessment Service; 2018.
|
20 |
Kim SO, Choi SE. Improving price-volume arrangement system by linking expenditure target with pharmaceutical price negotiation. Korean J Health Econ Policy 2011;17(3):1-21.
|
21 |
Rhee J, Shin G. Factors associated with fixed budgets for pharmaceuticals in European Countries. Yakhak Hoeji 2013;57(3):213-218.
|